DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge

AIDS

Volumn 27, Issue 18, 2013, Pages 2841-2851

  Koopman, Gerrit ^a   Beenhakker, Niels ^a   Nieuwenhuis, Ivonne ^a   Doxiadis, Gaby ^a   Mooij, Petra ^a   Drijfhout, Jan W ^b   Koestler, Josef ^c   Hanke, Tomas ^d   Fagrouch, Zahra ^a   Verschoor, Ernst J ^a   Bontrop, Ronald E ^a   Wagner, Ralf ^c   Bogers, Willy M J M ^a   Melief, Cornelis J M ^b,e  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ISA Pharmaceuticals   (Netherlands)

Author keywords

Conserved regions; HIV vaccine; Macaques; SIVmac251; Synthetic long peptides

Indexed keywords

ADENOVIRUS VECTOR; ALDARA CREAM; AMINO ACID; DNA VACCINE; GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONTANIDE ISA 720; PEGINTERFERON; PEGINTERFERON 1; PLASMID DNA; SIVCONSV VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SUBUNIT VACCINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE FREQUENCY; INFECTION PREVENTION; MUCOSA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE DRUG DOSE; ANIMAL; GENETICS; IMMUNOLOGY; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84888301911     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000047     Document Type: Article

References (39)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
3. Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design and preclinical evaluation of a universal HIV-1 vaccine. PLoS One 2007; 2:e984.
4. Borthwick NJ, Ahmed T, Rose A, Ebrahimsa U, Black A, Hayton E, et al. Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a phaseI/IIA clinical trial. AIDS Vaccine 2012. Boston, MA, USA; 2012. pp. P04.11.
5. Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, et al. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J Virol 2012; 86:4082-4090.
6. Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, Colloca S, et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012; 26:275-284.
7. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010; 40:1973-1984.
8. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351-360.
9. Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, et al. Comparing pooled peptides with intact protein for accessing crosspresentation pathways for protective CD8R and CD4R T cells. J Biol Chem 2009; 284:9184-9191.
10. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-1847.
11. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107:11895-11899.
12. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938-1941.
13. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
14. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
15. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific T cell responses. J Immunol 2003; 171:4320-4328.
16. Othoro C, Johnston D, Lee R, Soverow J, Bystryn JC, Nardin E. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun 2009; 77:739-748.
17. Raab D, Graf M, Notka F, Schodl T, Wagner R. The Gene Optimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol 2010; 4:215-225.
18. de Groot NG, Otting N, Robinson J, Blancher A, Lafont BA, Marsh SG, et al. Nomenclature report on the major histocompatibility complex genes and alleles of Great Ape, Old and New World monkey species. Immunogenetics 2012; 64:615-631.
19. Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixedmodality immunization: Increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 2008; 89:540-553.
20. Koopman G, Beenhakker N, Hofman S, Walther-Jallow L, Makitalo B, Mooij P, et al. Immunization with apoptotic pseudovirus transduced cells induces both cellular and humoral responses: A proof of concept study in macaques. Vaccine 2012; 30:2523-2534.
21. Koopman G, Mortier D, Hofman S, Koutsoukos M, Bogers WM, Wahren B, et al. Acute-phase CD4R T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques. J Gen Virol 2009; 90:915-926.
22. Loffredo JT, valentine LE, Watkins DI. Beyond Mamu-AM01R Indian rhesus macaques: continued discovery of new MHC Class I molecules that bind epitopes from the simian AIDS viruses. In: Korber BT, Brander C, Haynes BF, et al. editors. HIV molecular immunology Los Alamos: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2007. pp. 29-51.
23. Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, et al. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol 2010; 84: 2996-3003.
24. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008; 82:4844-4852.
25. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 2002; 415:331-335.
26. Arevalo-Herrera M, Vera O, Castellanos A, Cespedes N, Soto L, Corradin G, et al. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg 2011; 84:21-27.
27. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 2011; 3:258-263.
28. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5:1260-1265.
29. Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol 2012; 90:492-497.
30. Lattanzi L, Rozera C, Marescotti D, DAgostino G, Santodonato L, Cellini S, et al. IFN-alpha boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 2011; 216:537-547.
31. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, et al. IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 2012; 119:1407-1417.
32. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4RTh1 immunity with poly IC as adjuvant. J Exp Med 2009; 206:1589-1602.
33. Azizi A, Anderson DE, Torres JV, Ogrel A, Ghorbani M, Soare C, et al. Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008; 180:2174-2186.
34. Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, et al. Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000; 74:1694-1703.
35. Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu Rev Med 2010; 61:153-167.
36. Watkins DI. HIV vaccine development. Top HIV Med 2010; 18:35-36.
37. Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, et al. Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Recombinant Priming and Envelope Protein Boosting Elicits Localized, Mucosal IgA Immunity in Rhesus Macaques Correlated with Delayed Acquisition following a Repeated Low-Dose Rectal SIVmac251 Challenge. J Virol 2012; 86:4644-4657.
38. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
39. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, OConnor S, et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010:8.